S&P Futures
4,167.25 +20.50 (+0.49%) Dow Futures
32,892.00 +135.00 (+0.41%) Nasdaq Futures
13,316.25 +87.50 (+0.66%) Russell 2000 Futures
1,930.50 +8.70 (+0.45%) Crude Oil
88.08 -0.93 (-1.04%) Gold
1,795.70 +4.50 (+0.25%)
AN2 Therapeutics, Inc. (ANTX)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 8.74 |
| Open | 9.03 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 8.73 - 10.19 |
| 52 Week Range | 6.88 - 23.58 |
| Volume | |
| Avg. Volume | 65,385 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.67 |
- American City Business Journals
Bay Area's stream of new public companies has slowed to a weak trickle
After a busy 2021, the IPO pipeline for Bay Area companies has slowed to a trickle and the number of companies going public this year could be the lowest in five years.
- GlobeNewswire
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an initial focus on treatment-refractory MAC lung diseasePhase 2/3 pivotal trial expected to support regulatory approval for treatment-refractory MAC lung disease; Plan to use LPAD pathway MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing t
- Simply Wall St.
We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
